Related Experiment Video
Updated: May 26, 2026
04:01
Revealing the Ferroptotic Phenotype of Medulloblastoma
Published on: March 15, 2024
Deferasirox: pharmacokinetics and clinical experience
Renzo Galanello1, Simona Campus, Raffaella Origa
12a Clinica Pediatrica, Ospedale Regionale Microcitemie, Via Jenner s/n 09121 Cagliari, Italy. renzo.galanello@mcweb.unica.it
Expert Opinion on Drug Metabolism & Toxicology
|December 20, 2011
Summary
Deferasirox is an effective oral iron chelator for managing iron overload in anemia patients. Careful monitoring and dosing are recommended, though further research is needed for non-responders.
Area of Science:
- Hematology
- Pharmacology
Background:
- Iron overload is a serious complication of chronic transfusion therapy for anemias.
- Effective iron chelation is crucial to prevent severe morbidity and mortality.
- Deferasirox is an oral iron chelator used to treat iron overload.
Purpose of the Study:
- To review the efficacy and safety of deferasirox in iron-overloaded patients.
- To examine pharmacokinetic and pharmacodynamic data of deferasirox.
- To assess deferasirox use in thalassemia, sickle cell disease, and myelodysplastic syndromes.
Main Methods:
- Qualitative literature search using PubMed and key congress publications.
- Keywords included deferasirox, pharmacokinetic, pharmacodynamic, efficacy, and safety.
- Review of pivotal studies on deferasirox in various anemias.
Main Results:
- Deferasirox demonstrates efficacy in reducing iron overload.
- The safety profile of deferasirox is clinically manageable.
- Appropriate dosing and monitoring are essential for optimal outcomes.
Conclusions:
- Deferasirox treatment is effective with a manageable safety profile.
- Close monitoring of laboratory parameters and adverse events is recommended.
- Further research is needed for patients with inadequate response to iron chelators.
Related Concept Videos
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:10Pharmacokinetics: Overview
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV) administration...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...